KFAS
IMNM icon

Keating Financial Advisory Services’s Immunome IMNM Stock Holding History

Keating Financial Advisory Services’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$551 Hold
26
– – ﹤0.01% 2325
2026
Q1 		$569 Hold
26
– – ﹤0.01% 2238
2025
Q4 		$558 Buy
+26
New +$456 ﹤0.01% 1929

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Keating Financial Advisory Services's IMNM Position: Q2 2026 in Review

Keating Financial Advisory Services held its Immunome (IMNM) position steady in Q2 2026 at 26 shares worth $551. The position accounts for ﹤0.01% of the portfolio, ranked #2325.

Keating Financial Advisory Services first reported a position in IMNM in Q4 2025 and has held it in 3 quarters since. The position peaked at $569 in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Keating Financial Advisory Services held 26 shares of Immunome worth $551 as of Q2 2026.
  • Keating Financial Advisory Services left its Immunome share count unchanged in Q2 2026.
  • Immunome made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2325 holding.
  • Keating Financial Advisory Services first reported a position in Immunome in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Immunome position peaked at $569 in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.